



"NON SEMPER EA SUNT, QUAE VIDENTUR: DECIPIT FRONS PRIMA MULTOS"

SUPER-REFRACTORY MULTI-DRUG RESISTANT CONVULSIVE STATUS EPILEPTICUS DUE TO PROBABLE POST-INFECTIOUS AUTOIMMUNE LIMBIC ENCEPHALITIS: CASE REPORT

T. Rosso (MD), S. Lelli (MD), S. Prestera' (NPT), M. Sacchetto (NPT), G. Maccarrone (MD), R. Repice (MD). Neurology-ULSS 8, Castelfranco Veneto, Italy



Early recognition of autoimmune epilepsy is necessary to precocious immunological treatment, but its diagnosis is still challenging. Paraclinical biomarkers are supportive. Autoimmune epilepsy and encephalitis are linked to neural-specific autoantibodies. Cerebrospinal fluid examination can confirm central nervous system inflammation. Serological markers of systemic autoimmune disorders must be investigated. Brain MRI can show altered focal signals. Functional brain imaging (FDG-PET) can reveal increased focal metabolism. EEG is mandatory to protect brain against non-convulsive status epilepticus.



A young man 39 y.o. was admitted in our Neurological Unit at the end of February for a referred 30 minutes episode of aphasia, confusion, agitation and temperature from the previous night. In the Emergency Department he had a generalized seizure, treated with clonazepam. He had already been discharged twice from the E.D. in the last 10 days for fever, with antibiotics prescriptions.


Clinical presentation aroused the suspicion of HSV encephalitis. He had urgent LP and brain MRI, which revealed a faint ill-defined hyper-intensity of the left hippocampus and a minimal bilateral mesial lobe enlargement.

The recurrence of untreatable convulsive generalized seizures, required admission in the Intensive Care Unit for the next 60 days for pharmacological coma. He was submitted to extensive, repeated laboratoristic sierological and liquoral (infective and autoimmunitary) testing, monthly brain RMI and 2 total-body FDG-PET (looking for viruses, bacteria, JCV or evidences of central nervous system inflammation or neoplasms). Continuous EEG (cEEG) monitoring was performed to induce efficient burst-suppression pattern (by propofol, midazolam and sodium thiopenthal) and to reduce brain damage due to refractory non-convulsive status epilepticus, while a concomitant aggressive add-on antiepileptic drugs strategy was undertaken. Three times pharmacological coma was re-induced because focal epileptic activities erupted on EEG (with congruent faciobrachial seizures) promptly, when sedation was decreased.

After 30 days, after all the antibiotics and antiviral therapies, although seronegative repeated neuronal specific autoantibodies, a steroid immunotherapy trial with i.v. Metilprendisolone 1000 mg daily for 5 days was done and we noted a first improvement on electric seizures frequency. A second trial was given the month after. At the end of April he was readmitted in the Neurological ward

FEBRUARY	EEG
----------	-----

7 µV/mm C4-P4			4 - 0	_			
7 µV/mm				~			
C3-P3 7 µV/mm				~~~~			
P4-O2 7 μV/mm					N		M.a. A
P3-01 7 µV/mm				7 µV/mm		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
Fp2-F8 7 µV/mm	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Ny/w~~~	√ 7 µV/mm			
Fp1-F7 7 µV/mm	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	M	man Manung	7 µV/mm			
F8-T4 7 µV/mm	mphilip		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	FB-C3 7 µV/mm C4-94 7 uV/mm			
F7-T3 7 µV/mm				7 µV/mm C3-P3			
T4-T6				7 µV/mm			
7 µV/mm T3-T5		~ ~~~~	A. A. A.	7 µV/mm			
7 µV/mm T6-O2	- make to the second	~ ~		7 µV/mm			Aut
7 µV/mm TS-O1 7 µV/mm				7 µV/mm	- Martin		
				7 µV/mm			Muran
Pz-Cz 7 µV/mm Cz-Pz				7 µV/mm F7-T3	- Mar Jammer		www.
7 µV/mm EMG		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		7 µV/mm T4-T6 7 µV/mm			
10 mV/mm MK-RF				7 µV/mm T3-T5			
2 mV/mm TM-RF				7 µV/mm T6-02 7 µV/mm			4.0
20 µV/mm							
				T5-01 7 µV/mm			
28/02/2016 19:40	11		1	Pz-Cz 9:463 7 µV/mm			
				Cz-Pz 7 µV/mm			WV
				EMG 10 mV/mm			
				MK-RF 2 mV/mm			




CSF 25.02: not clear; cells 29 (mononucleated 80%), protein 106; albumin index 17.6 (n.v. <7); negative HSV-PCR , coltures LAB TESTING: negative serology for HBV, HCV, HIV1/2,HSV1/2, EBV, CMV, VZV, parotite, B.B.; gray zone: Coxachievirus, Echovirus,

THERAPY: propofol (up to 7 mg/kg/h); midazolam (up to 0.8 mg/kg/h + boli) Valproic acid (1.2 g/die)+ Phenitoine (up to 1.5 g/die)

Aciclovir; Ceftriaxone; Ampicillina; azitromicin

MARCH EEG	
IVIARUN EEG	
	a market and a second and a second and a second
	un manual and a second and a
" war	
mm www.m.m.m.m.m.m.m.m.m.m.m.m.m.m.m.m.m	
m how which was how many provident of 7 within w	
84.64	
P of the Western of A free 1 and a free state of the stat	
WWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW	
Warming and March March March Card and Card an	
" WMWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW	
m WWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW	
" When proved you want when a wind the second state of the second	
Werter and Marker Way Marker and Marker The Marker and Ma	
IMANAAMIN'NAMIN'NAMIN'NAMIN'	
Contraction of the Annual Annual Contraction of the	The second secon
	when the property of the prope
7 M M M M M M M M M M M M M M M M M M M	
nanghathaurina an ing anghanang manakanan diperantirangkan ang kanghangkangkangkangkangkangkangkangkangkangk	
75-01 7.V/mm	
7 g/ymm F2 C2 7 g/ymm	
7 J//mm C2-Pz	
	man have been been the second have been the second and the second
EMG 10 mV/mmh MK.PF	- Per prove the
2 mV/mm	the property of the property o
TM-RF 20 µ//mm	
	EAS V V V V V V V V V V V V V V V V V V V
16/02/2016 06 53:08	MC67
	TARF A A A A A A A A A A A A A A A A A A
	17/08/2016 22:31-02 22:31:02




CSF 02.03: 1 cell, proteins 36; negative
genomic research for -HSV, -enterovirus, -echovirus, -VZV, -CMV, -EBV, -HSV, -HSV6, -HSV7,-parechovirus, -Neisseria meningitidis
CFS 09.03: negative CJD quick-test; increase
14.3.3 and tau protein 8>2400pg/ml)
LAB TESTING: pos IgM against Mycoplasma
Pneumoniae; pos urocolture: P.a., E.f., Citrob.
C reactive protein 58.27 (n.v, <0.5) neg serolog
TBE, Ab against-thyroid, -Hu, -YO, -Ri, ANA,
ENA, ANCA; neg antibodies (CSF/Blood)
against -GAD, -VGKC (LGI1 and CASPR2),
-NMDA R, -GABA r, -AMPA R

THERAPY:modified midazolam (up to **1.3 mg/kg/h**) and propofol + sodium thiopenthal (up to **5 mg/kg/h**); VPA+ PHT+ Lacosamide (LCM 300 mg/die)+ Levetiracetam (LVT3 g/die)+ lamotrigine (LMT 100 mg)

first i.v. Metilprednisolone 1 g daily for 5 days

APRIL EEG: motor focal seizures (right shoulder jerks)

			non w														
																	www.www.www.www.www.www.www.www.www.ww
uv/mm	when	www.	Myrumut	mphi	ly with	whenter	pallyahant	MMM	www./m	manal	manyle ling	marge would	haa faaba farrad yo	the property	nun	producents	and management and a support of the second o
P4 µV/mm~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	mm	MAN	www	www	h~ man	www	1. when we	www	MANA	Vnn	mpph	man	mm	when	warn	man	Man man man man and the second seco
P3 µV/mm~~~~/	man	mm	Maryman	mon	par you	www	low when the love	loww	umpow	when	when	mann	hand	Marin	man	mather	when a provide the second and the second second second and the second seco
02 µV/mm	mallin	walkhi	marchant	Mahar	ngegyally	Apple 14	MARWY	hunh	Maple	WARN	w. A.H.UMI	Anthorization	MANNA	Monthali	J. Apple	mother	Winanananananananananananananananananana
			INW														Al- www.www.www.www.www.www.www.www.www.ww
-F8 1/4, 14	MANN	inni	Minter	mins	min	Jahan	Virme S	ζM	martin	in Ka	amah	Moun	mar	n. M.	J. Y.V.	mun	and of the second and the second of the second s
-F7	MMAN	MAAN	Maria	Manual	heren	American	MAMA	whi	makriw	Amar	MA	manan	walke	n.A.h.	M	n. Allow	and the particular and the second for the second for the second
14 ALM	did tala	an mil	alisale dischool	and the	han de	h h iv	al des 1	million	1 Juli	h in the A	an alaan	فاسر وبالعوران	a line as	de de seu	Muruda	male was	Marine Marine and Marine Ma
W/mm/	e opene open and a ho	A Add	Ann and	A Junio	1 m 1 m	n yn war i	and a	n wany ye i	wry riv	a a ch	er er frage	and the first of	and the second		Markey P	ուս ու ազերաց ԱԼԼ է Ե. Ե. Ե.	Manufacture and a second and the second and the second and the second second second second second second second
W/mm	MAR	k histil	a ja ja seit	m		UI		M	M V V M	N N N	rrenzia 	A luuu	en ti di a	n h h h h	che fe de l'an	program ly av	r Leventer and a second and a second and a second of the second of the production of the second and the second
M. P\B	- ህንዱ/ግ/ ነ	ምዋዋ	Y MWW	WWW	nauh	IV W W	ingge angen y	rvvv	wyp	(YYM)	WYYYY	uurumy	nipit unu	TY WM	MYMM	in him i	V the advancement of a share a single of the share a single of the share a shar
10/mm w 1	1 a da	LA A B L															
15 JV/mm JV/mm	utility	upperforme	Munimur	hum	reality	WYYYPY	MINAM	PMMA	mfral Mill	WWW I	MANY NU	All All Vitwain	panalation	性性性	MVK/MAAA A A A	noppy	had A new northean a contribution of a strategic and an operative and a second strategic barren to second strategic and the strategic with
N/mm	YW.UV	XMMV	MMW.V*	4)4M	WW	MMMA	www.wi	WY Wit	NMW14	MANA	W. W. Unite	MN/VN	1 M WAR	41/WW	AN WW	"MY YAM	Man I have been a sing in the second second a second
N/mm	YW.UV	XMMV	MMW.V*	4)4M	WW	MMMA	www.wi	WY Wit	NMW14	MANA	W. W. Unite	MN/VN	1 M WAR	41/WW	AN WW	"MY YAM	Mana manager and a star
N/mm	YW.UV	XMMV	MMW.V*	4)4M	WW	MMMA	www.wi	WY Wit	NMW14	MANA	W. W. Unite	MN/VN	1 M WAR	41/WW	AN WW	"MY YAM	Man Markan and a second a se
//mm///// 1 //mm////	ANN AN ANN AN	WWW WWW		n yan Waliya Mana	NVIVN RANK MRANK			www. Will	lanara		no hall	M Marian			M	awaaa k	Man Marine and the second and the se
(/mm///// //mm////	ANN AN ANN AN	WWW WWW	MMW.V*	n yan Waliya Mana	NVIVN RANK MRANK			www. Will	lanara		no hall	M Marian			M	awaaa k	Mary Mary Marine Mar Marine Marine Ma Marine Marine Ma
μV/mm O1 μV/mm Cz μV/mm	ANN AN ANN AN	WWW WWW		n yan Waliya Mana	NVIVN RANK MRANK			www. Will	lanara		no hall	M Marian			M	awaaa k	
N/mm 01 N/mm 2 N/mm	ANN AN ANN AN	WWW WWW		n yan Waliya Mana	NVIVN RANK MRANK			www. Will	lanara		no hall	M Marian			M	awaaa k	Man Marine and the second and the se



CSF 14.04: proteins 60, cells 1; isoelectrofocusing: mirrow pattern (3 oligoclonal bands-OCB- in serum and in CSF), blood-brain barrierdisruption (9.109, n.v. <8), not endogenous synthesis;

LAB TESTING: pos urocolture: P.a.;pos; lung aspirate: S.. m.; neg Ab against-Tyreoperoxidase; neg antibodies against -GAD, Continue midazolam Stop thiopental, propofol; stop lamotrigine PHT (750 mg)+ VPA (1.6 g)+ LVT (**4** g)+ LCM (300 mg)+

THERAPY:

clonazepam (60 mg)

second i.v. Metilprednisolone 0.5 g daily for 3 days


	1 52,1kHz 1 /Ingenia 1,5T 79 L - 274	neg antibodies against -GAD, -VGKC (LGI1 and CASPR2), -NMDA R, -GABA r, -AMPA R
MAY EEG: sensory focal seizures (left side hot fashes)	95 Study Date:06/05/2016 Study Time:11:07:28 MRN: [L]	THERAPY: Stop midazolam PHT (300 mg)+ VPA (2.5 g)+ LVT (4 g)+ LCM (400 mg) + clonazepam (30 mg)+ clobazam (30 mg)

JUNE EEG: motor focal sei	zures (right shoulder	jerks) + sensory foca
seizures (left side hot fashe	5)	

Fp2-F4 7 µV/mm	and the second and th
	have a second and the
	have do not a second and the second
F3-⊂3 7 µV/mm	and an an and an
	here for a second ward ward ward ward ward ward ward war
C3-P3 7 µV/mm	have the second with the second of the second s
P4-O2 7 μV/mm	have a second where the second
P3-O1 7 μV/mm	hours from the second wards and the second second and the second
Fp2-F8 7 μV/mm	have not a second war and the second s
Fp1-F7 7 μV/mm	In market and a second and the secon
F8-T4 7 μV/mm	when we
F7-T3 7 μV/mm	have been to a second
T4-T6 7 μV/mm	for a far a
T3-T5 7 μV/mm	hamal market was a superior of the second and the s
	mound and the second
	have a second with the second of the second
	have the second and t
Cz-Pz 7 μV/mm	have presented and the second and th
EMG DX 10 mV/mm	

	7 µV/mm
JULY EEG:	Fp1-F3 7 µV/mm
	F4-C4 7 µV/mm
VPA (2.5 g)+	F3-C3 7 µV/mm
V / (2.5 y)+	C4-P4 7 µV/mm
	C3-P3 7 µV/mm
LVT (3 g)+	P4-02 7 W/mm MMM
	P3-01 10/mm Mump
CM(400 mm)	Fp2-F8 7 µV/mm
LCM (400 mg) +	Fp1-F7 7 µV/mm
	F8-T4 7 µV/mm
CLZEP (2 mg)	F7-T3 7 uV/mm
	74-76 7 µV/mm Myr ww
	72,75
TPM (100 mg)	7 µV/mm What what what T6-02
	7 µV/mm WWW
ourth Metilprendinosole	7 uV/mm MMMMM
	7 µV/mm www.www Cz-Pz
	7 µV/mm
1 g daily for 5 days,	100 µV/mm
· a wany ion a uaya,	100 µV/mm MK-RF
hon alous to a sul	500 µV/mm TM-RF
hen slow tapering per os	100 µV/mm
and the stand her of	
	12:14:31

262-64 W/mm p1-F3 W/mm 4C4 W/mm 4C4 W/mm 4C4	man from the second sec		and reason how a		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Winn marken war	muniter and the second second	man water and the second secon	and and and a second and second an	man when when we want when when when when when when when when	
-01 Winn Murselwww. May Milling Mur 248 Winn - Wanner May Mar	monorman and and an		man man man	man from from from for the former of the for	white where
mm manufacture from mm manufacture from mm from the former of the former	and a start and the second sec	mun marine and mer	and when he was	man han have	n hi
m manager when the full with the full of t	marting and a second and a second	man and and a second	mmmy manner	man a second man	ward ward Man
				mounter and	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
121431					
				11	21451



AUGUST EEG

TM-RF 100 µV/	mm	09.21.2
500 µV/	mm	
7 µV/mr MK-RF		
cz.Pz	"	burburburburburburburburburburburburburb
z.Cz	a non have an and a second and the s	
5.01 µV/mm	Annow my marker and	a data standar Mannah Man
6-02 w//mm	man and the second seco	And and the second of the seco
yiv/mm		
uV/mm 3-15	www.www.www.www.www.www.www.www.www.ww	warmenter and a second and a
µV/mm 1.76	man	and a second and a
.тз	man market was the second of t	and the second and the se
.T4 ///mm	many and the second and the second of the second se	and the property of the second water and the property of the second se
1.F7 V/mm	man man and a second	a manufacture and a star when the second and the se
∣.F8 V/mm	and the second second and the second se	
v/mm	and a second and the second se	and the second and the second and the second s
//mm	and management and the second and th	and the second sec
2	the more thank the second with the second se	month and the second seco
	warman	man and the second
4 /mm	Variation and the second of the second secon	and the second s
5 /mm		and and a second a second a second
imm "	and the second of the second o	Manual and a second
mm	and the second s	manufally and a second and as second and a
mm) 3		
4	wanter ware where the second state and the second s	

Study Date: 15/06/2018		THERAPY: Stop phenitoine, clobazam
Study Time:8.56,36 MRN:	CSF: neg Ab against -NMDA R; -AMPA R; -GABAb; mGLU- R1; -VGKC (LGI1, CASPR2)	(Frisium) VPA (2.5 g)+ LVT (3 g)+ LCM (400 mg)+ CLZEP (20 mg)
		third Metilprednisolone 1 g daily for 3 days, followed by IG i.v. 0.4 g/kg/day for 5 days
	SEPTEMBER EEG: VPA (2.5 g) + LVT (3 g) + LCM (400 mg) + TPM (100 mg) + CLZEP (2 mg) + CLBZAM (10 mg)	
	7 5.000 7 5.000 <t< td=""><td></td></t<>	

